litlas
Log inCreate account

Peter J. Neumann

Active 1994–2024

119
Papers
21,660
Citations
79
h-index
117
i10-index

Citations

Citations per year for Peter J. Neumann1993: 1 citations1994: 1 citations1995: 5 citations1996: 4 citations1997: 10 citations1998: 3 citations1999: 8 citations2000: 26 citations2001: 49 citations2002: 58 citations2003: 67 citations2004: 79 citations2005: 89 citations2006: 99 citations2007: 74 citations2008: 86 citations2009: 83 citations2010: 88 citations2011: 77 citations2012: 79 citations2013: 88 citations2014: 88 citations2015: 82 citations2016: 112 citations2017: 124 citations2018: 164 citations2019: 637 citations2020: 891 citations2021: 712 citations2022: 479 citations2023: 313 citations2024: 541 citations2025: 222 citations2026: 12 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,589 citing papers, 32.8% of this breakdownUnited Kingdom: 810 citing papers, 10.2% of this breakdownCanada: 508 citing papers, 6.4% of this breakdownAustralia: 338 citing papers, 4.3% of this breakdownNetherlands: 337 citing papers, 4.3% of this breakdownChina: 320 citing papers, 4% of this breakdownGermany: 284 citing papers, 3.6% of this breakdownItaly: 232 citing papers, 2.9% of this breakdownSwitzerland: 164 citing papers, 2.1% of this breakdownFrance: 155 citing papers, 2% of this breakdownSpain: 151 citing papers, 1.9% of this breakdownSweden: 147 citing papers, 1.9% of this breakdown
0%32.8%Other 23.6%

Institutions

Fields

  • Medicine63.3%
  • Economics, Econometrics and Finance15.8%
  • Health Professions4.9%
  • Biochemistry, Genetics and Molecular Biology3.9%
  • Psychology1.9%
  • Mathematics1.4%
  • Other8.8%

Topics

  • Health Systems, Economic Evaluations, Quality of Life7.5%
  • Dementia and Cognitive Impairment Research3%
  • Healthcare cost, quality, practices1.8%
  • Economic and Financial Impacts of Cancer1.7%
  • Pharmaceutical Economics and Policy1.4%
  • Healthcare Policy and Management1.3%
  • Other83.3%

Coauthors

All papers

Open in search
  1. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses

    Authors: Gillian D Sanders, Peter J. Neumann, Anirban Basu, Dan W. Brock, David Feeny, Murray Krahn, Karen M. Kuntz, David O. Meltzer, Douglas K Owens, Lisa A. Prosser, Joshua A. Salomon, Mark Sculpher, Thomas A Trikalinos, Louise B. Russell, Joanna E. Siegel, Théodore G. Ganiats - JAMA 2016 cited by 3,012

  2. Updating Cost-Effectiveness — The Curious Resilience of the 50,000-per-QALY Threshold

    Authors: Peter J. Neumann, Joshua T. Cohen, Milton C. Weinstein - New England Journal of Medicine 2014 cited by 2,250

  3. Cost-effectiveness Thresholds Used by Study Authors, 1990-2021

    Authors: Peter J. Neumann, David D. Kim - JAMA 2023 cited by 155

  4. Perspective and Costing in Cost-Effectiveness Analysis, 1974–2018

    Authors: David D. Kim, Madison C. Silver, Natalia Kunst, Joshua T. Cohen, Daniel A. Ollendorf, Peter J. Neumann - PharmacoEconomics 2020 cited by 272

  5. Economic Impact of Childhood and Adult Attention-Deficit/Hyperactivity Disorder in the United States

    Authors: Jalpa A. Doshi, Paul Hodgkins, Jennifer Kahle, Vanja Sikirica, Michael J. Cangelosi, Juliana Setyawan, M. Haim Erder, Peter J. Neumann - Journal of the American Academy of Child & Adolescent Psychiatry 2012 cited by 435

  6. Treatment of colorectal liver metastases in Germany: a ten-year population-based analysis of 5772 cases of primary colorectal adenocarcinoma

    Authors: Christina Hackl, Peter J. Neumann, Michael Gerken, Martin Loss, Monika Klinkhammer‐Schalke, Hans J. Schlitt - BMC Cancer 2014 cited by 329

  7. Using Real-World Data for Coverage and Payment Decisions: The ISPOR Real-World Data Task Force Report

    Authors: Louis P. Garrison, Peter J. Neumann, Pennifer Erickson, Deborah A. Marshall, C. Daniel Mullins - Value in Health 2007 cited by 705

  8. The influence of time horizon on results of cost-effectiveness analyses

    Authors: David D. Kim, Colby Wilkinson, Elle Pope, James D. Chambers, Joshua T. Cohen, Peter J. Neumann - Expert Review of Pharmacoeconomics & Outcomes Research 2017 cited by 98

  9. Patterns of Statin Use in a Real-World Population of Patients at High Cardiovascular Risk

    Authors: Iris Lin, Jennifer Sung, Robert J. Sanchez, Usha G. Mallya, Mark I. Friedman, Mary Panaccio, Andrew Koren, Peter J. Neumann, Joseph Menzin - Journal of Managed Care & Specialty Pharmacy 2016 cited by 90

  10. Racial and Ethnic Differences in Hospice Use and Hospitalizations at End-of-Life Among Medicare Beneficiaries With Dementia

    Authors: Pei‐Jung Lin, Yingying Zhu, Natalia Olchanski, Joshua T. Cohen, Peter J. Neumann, Jessica D. Faul, Howard Fillit, Karen M. Freund - JAMA Network Open 2022 cited by 69

  11. Developing Criteria for Health Economic Quality Evaluation Tool

    Authors: David D. Kim, A. Lauren, Patricia G. Synnott, Tara A. Lavelle, Lisa A. Prosser, John B. Wong, Peter J. Neumann - Value in Health 2023 cited by 64

  12. Cost-effectiveness of exome and genome sequencing for children with rare and undiagnosed conditions

    Authors: Tara A. Lavelle, Xue Feng, Marlena Keisler, Joshua T. Cohen, Peter J. Neumann, Daryl Prichard, Brock E. Schroeder, Daria Salyakina, Paula S. Espinal, Samuel B Weidner, Jill L. Maron - Genetics in Medicine 2022 cited by 63

  13. Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low- and Middle-Income Countries: Trends in Cost-per-DALY Studies

    Authors: Ashley A. Leech, David D. Kim, Joshua T. Cohen, Peter J. Neumann - Value in Health 2018 cited by 179

  14. Potentially avoidable hospitalizations among Medicare beneficiaries with Alzheimer's disease and related disorders

    Authors: Pei‐Jung Lin, Howard Fillit, Joshua T. Cohen, Peter J. Neumann - Alzheimer s & Dementia 2013 cited by 140

  15. Prevalence and Impact of Medical Comorbidity in Alzheimer's Disease

    Authors: P. Murali Doraiswamy, José de León, Jeffrey L. Cummings, Deborah B. Marin, Peter J. Neumann - The Journals of Gerontology Series A 2002 cited by 267

  16. An Overview of Value, Perspective, and Decision Context—A Health Economics Approach: An ISPOR Special Task Force Report [2]

    Authors: Louis P. Garrison, Mark V. Pauly, Richard J. Willke, Peter J. Neumann - Value in Health 2018 cited by 187

  17. Medicare Expenditures of Individuals with Alzheimer's Disease and Related Dementias or Mild Cognitive Impairment Before and After Diagnosis

    Authors: Pei‐Jung Lin, Yue Zhong, Howard Fillit, Er Chen, Peter J. Neumann - Journal of the American Geriatrics Society 2016 cited by 133

  18. Lethality of Alzheimer Disease and Its Impact on Nursing Home Placement

    Authors: H. Michael Arrighi, Peter J. Neumann, Ivan Lieberburg, Raymond J. Townsend - Alzheimer Disease & Associated Disorders 2010 cited by 121

  19. The History and Future of the “ISPOR Value Flower”: Addressing Limitations of Conventional Cost-Effectiveness Analysis

    Authors: Peter J. Neumann, Louis P. Garrison, Richard J. Willke - Value in Health 2022 cited by 86

  20. Orphan Drugs Offer Larger Health Gains but Less Favorable Cost-effectiveness than Non-orphan Drugs

    Authors: James D. Chambers, Madison C. Silver, Flora Berklein, Joshua T. Cohen, Peter J. Neumann - Journal of General Internal Medicine 2020 cited by 54

  21. Racial and Ethnic Differences in Knowledge About One's Dementia Status

    Authors: Pei‐Jung Lin, Joanna Emerson, Jessica D. Faul, Joshua T. Cohen, Peter J. Neumann, Howard Fillit, Allan T. Daly, Nikoletta M. Margaretos, Karen M. Freund - Journal of the American Geriatrics Society 2020 cited by 46

  22. Analytic Considerations in Applying a General Economic Evaluation Reference Case to Gene Therapy

    Authors: Michael Drummond, Peter J. Neumann, Sean D. Sullivan, Frank-Ulrich Fricke, Sean Tunis, Omar Dabbous, Mondher Toumi - Value in Health 2019 cited by 92

  23. Cost-Effectiveness of PET in the Diagnosis of Alzheimer Disease

    Authors: Pamela M. McMahon, S Araki, Eileen A. Sandberg, Peter J. Neumann, G. Scott Gazelle - Radiology 2003 cited by 82

  24. Examining the Value and Quality of Health Economic Analyses: Implications of Utilizing the QHES

    Authors: Joshua J. Ofman, Sean D. Sullivan, Peter J. Neumann, Chiun‐Fang Chiou, James M. Henning, Sally Wade, Joel W. Hay - Journal of Managed Care Pharmacy 2003 cited by 366